CN107835688A - 用于治疗阿尔茨海默病的神经元钙池操纵的钙进入途径的活化 - Google Patents

用于治疗阿尔茨海默病的神经元钙池操纵的钙进入途径的活化 Download PDF

Info

Publication number
CN107835688A
CN107835688A CN201680040043.XA CN201680040043A CN107835688A CN 107835688 A CN107835688 A CN 107835688A CN 201680040043 A CN201680040043 A CN 201680040043A CN 107835688 A CN107835688 A CN 107835688A
Authority
CN
China
Prior art keywords
trpc6
compound
spines
mice
stim2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680040043.XA
Other languages
English (en)
Chinese (zh)
Inventor
伊利亚·贝兹普罗兹万内
张华�
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN107835688A publication Critical patent/CN107835688A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680040043.XA 2015-05-08 2016-05-04 用于治疗阿尔茨海默病的神经元钙池操纵的钙进入途径的活化 Pending CN107835688A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562159083P 2015-05-08 2015-05-08
US62/159,083 2015-05-08
PCT/US2016/030704 WO2016182812A1 (en) 2015-05-08 2016-05-04 Activation of neuronal store-operated calcium entry pathway for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
CN107835688A true CN107835688A (zh) 2018-03-23

Family

ID=57248333

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680040043.XA Pending CN107835688A (zh) 2015-05-08 2016-05-04 用于治疗阿尔茨海默病的神经元钙池操纵的钙进入途径的活化

Country Status (6)

Country Link
US (1) US20180147206A1 (enExample)
JP (1) JP2018515507A (enExample)
KR (1) KR20180004242A (enExample)
CN (1) CN107835688A (enExample)
HK (1) HK1250658A1 (enExample)
WO (1) WO2016182812A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110759985A (zh) * 2018-07-27 2020-02-07 中国人民解放军军事科学院军事医学研究院 一种用于微波辐射致神经元钙信号调节的生物标志物Orai2蛋白

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2676100C1 (ru) * 2018-10-05 2018-12-26 федеральное государственное автономное образовательное учреждение высшего образования "Санкт-Петербургский политехнический университет Петра Великого" (ФГАОУ ВО "СПбПУ") Применение производных пиперазина для лечения болезни Альцгеймера и деменций альцгеймеровского типа с нарушенной внутриклеточной кальциевой сигнализацией
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1370526A (zh) * 2001-02-12 2002-09-25 沃尼尔·朗伯公司 治疗核因子－kb介导的疾病和障碍的方法
CN102574816A (zh) * 2009-07-21 2012-07-11 哈佛大学校长及研究员协会 有效的小分子自噬抑制剂及其使用方法
US20140271668A1 (en) * 2013-03-15 2014-09-18 Georgetown University Increasing parkin activity by administering a deubiquitinating enzyme inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598344B2 (en) * 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1370526A (zh) * 2001-02-12 2002-09-25 沃尼尔·朗伯公司 治疗核因子－kb介导的疾病和障碍的方法
CN102574816A (zh) * 2009-07-21 2012-07-11 哈佛大学校长及研究员协会 有效的小分子自噬抑制剂及其使用方法
US20140271668A1 (en) * 2013-03-15 2014-09-18 Georgetown University Increasing parkin activity by administering a deubiquitinating enzyme inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KENG-CHANG TSAI ETC.: "The first pharmacophore model for potent NF-kB inhibitors", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110759985A (zh) * 2018-07-27 2020-02-07 中国人民解放军军事科学院军事医学研究院 一种用于微波辐射致神经元钙信号调节的生物标志物Orai2蛋白
CN110759985B (zh) * 2018-07-27 2021-11-09 中国人民解放军军事科学院军事医学研究院 一种用于微波辐射致神经元钙信号调节的生物标志物Orai2蛋白

Also Published As

Publication number Publication date
US20180147206A1 (en) 2018-05-31
JP2018515507A (ja) 2018-06-14
KR20180004242A (ko) 2018-01-10
WO2016182812A8 (en) 2017-03-09
WO2016182812A1 (en) 2016-11-17
HK1250658A1 (zh) 2019-01-11

Similar Documents

Publication Publication Date Title
Hur γ-Secretase in Alzheimer’s disease
Zhang et al. Store-operated calcium channel complex in postsynaptic spines: a new therapeutic target for Alzheimer's disease treatment
Barten et al. Therapeutic strategies for Alzheimer’s disease
Avetisyan et al. Mitochondrial dysfunction in neocortex and hippocampus of olfactory bulbectomized mice, a model of Alzheimer’s disease
Boscia et al. The expression and activity of KV3. 4 channel subunits are precociously upregulated in astrocytes exposed to Aβ oligomers and in astrocytes of Alzheimer's disease Tg2576 mice
Trinh et al. Adenosine receptor signalling in Alzheimer’s disease
Yang et al. Sulforaphene, a CDK5 Inhibitor, attenuates cognitive deficits in a transgenic mouse model of Alzheimer’s disease via reducing Aβ Deposition, tau hyperphosphorylation and synaptic dysfunction
CN107835688A (zh) 用于治疗阿尔茨海默病的神经元钙池操纵的钙进入途径的活化
Yue et al. Interaction between extracellular ATP5A1 and LPS alleviates LPS-induced neuroinflammation in mice
KR102590485B1 (ko) 신규 타우 단백질-매개 퇴행성 신경질환 치료제 및 그의 스크리닝 방법
AU2017353446A1 (en) Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases
WO2020064979A1 (en) Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
US20230073000A1 (en) Improved Cell-Permeable Modified Parkin Recombinant Protein for Treatment of Neurodegenerative Diseases and Use Thereof
CN110623960B (zh) 一种小分子化合物在制备治疗阿尔茨海默病的药物中的应用
WO2013098588A1 (en) Use of calcilytic drugs as a pharmacological approach to the treatment and prevention of alzheimer's disease, alzheimer's disease-related disorders, and down's syndrome neuropathies
Tian et al. GALM Alleviates Aβ Pathology and Cognitive Deficit Through Increasing ADAM10 Maturation in a Mouse Model of Alzheimer’s Disease
Lorke et al. α7-nicotinic acetylcholine receptors and β-amyloid peptides in Alzheimer’s disease
Tautou et al. A ß-Secretase Modulator Decreases Tau Pathology and Preserves Short-Term Memory in a Mouse Model of Neurofibrillary Degeneration
US20130102538A1 (en) Method of treating alzheimer's disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity
WO2015073524A1 (en) Novel methods of treating or preventing alzheimer's disease
US20240226062A1 (en) Methods and compositions for the treatment of disorders characterized by a kidins220 dysfunction in a subject
Lawrence N-terminal beta amyloid fragments regulate nicotinic acetylcholine receptors
Jeon et al. ACE1 Does Not Influence Cerebral Aβ Degradation or Amyloid Plaque Accumulation in 5XFAD Mice
KR20250010000A (ko) 신규 펩타이드 및 그의 용도
Pradhan Activation of translocator protein by XBD173 ameliorates cognitive deficits and neuropathology in an Alzheimer’s mouse model

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1250658

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180323

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1250658

Country of ref document: HK